Cargando…

Prospective Comparison of 18-FDG PET/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant

SIMPLE SUMMARY: Over the past decade, the imaging of multiple myeloma has evolved with the increasing use of modern imaging techniques such as 18-FDG PET/CT and MRI. Both imaging modalities have high sensitivity for the detection of bone involvement. 18-FDG PET/CT may help assess treatment response,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mesguich, Charles, Latrabe, Valérie, Hulin, Cyrille, Lascaux, Axelle, Bordenave, Laurence, Hindié, Elif, Marit, Gerald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074107/ https://www.ncbi.nlm.nih.gov/pubmed/33923781 http://dx.doi.org/10.3390/cancers13081938

Ejemplares similares

Choline PET/CT in Multiple Myeloma
por: Mesguich, Charles, et al.
Publicado: (2020)

Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial
por: Mesguich, Charles, et al.
Publicado: (2020)

New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma
por: Mesguich, Charles, et al.
Publicado: (2016)

Breast cancer: initial workup and staging with FDG PET/CT
por: Groheux, David, et al.
Publicado: (2021)

The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors
por: Hindié, Elif
Publicado: (2017)

PET/CT in Multiple Myeloma: Beyond FDG
por: Matteucci, Federica, et al.
Publicado: (2021)

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?
por: Michaud-Robert, Anne-Victoire, et al.
Publicado: (2020)

Prognostic Impact of (18)FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer
por: Groheux, David, et al.
Publicado: (2012)

Effect of dosimeter’s position on occupational radiation extremity dose measurement for nuclear medicine workers during (18)F-FDG preparation for PET/CT
por: Salesses, Fabien, et al.
Publicado: (2016)

Detection of Extramedullary Multiple Myeloma in Liver by FDG-PET/CT
por: Kim, Dae-Weung, et al.
Publicado: (2013)

Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment
por: Bosch, Karen D., et al.
Publicado: (2019)

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
por: Zamagni, Elena, et al.
Publicado: (2023)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Induction Treatment in Transplant-eligible Multiple Myeloma
por: Quinn, J., et al.
Publicado: (2021)

PET/CT F18-FDG with soft tissue plasmacytomas in multiple myeloma
por: Martí, Alejandro, et al.
Publicado: (2021)

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
por: Bobin, Arthur, et al.
Publicado: (2020)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
por: Bailly, Clément, et al.
Publicado: (2019)

‘Double cortex’ sign on FDG-PET/CT in diffuse band heterotopia
por: Tripathi, Madhavi, et al.
Publicado: (2013)

Diffusion-Weighted MRI and FDG-PET in Diagnosis of Endometrial Stromal Nodule
por: Maruyama, Shunsuke, et al.
Publicado: (2015)

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Polymicrobial Pyomyositis in a Patient with Suspected Myeloma on (18)F-FDG PET-CT
por: Kalra, Simran, et al.
Publicado: (2022)

Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist (68)Ga-RM2 and (18)F-FDG in breast cancer samples
por: Morgat, Clément, et al.
Publicado: (2019)

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022)

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
por: Elboga, Umut, et al.
Publicado: (2022)

Semi-quantitative FDG parameters predict survival in multiple myeloma patients without autologous stem cell transplantation
por: Lee, Hyunjong, et al.
Publicado: (2023)

18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?
por: Zukovs, Romans, et al.
Publicado: (2022)

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Interest of Pet Imaging in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2019)

(18)F-FDG PET/CT in Primary AL Hepatic Amyloidosis Associated with Multiple Myeloma
por: Son, Youn Mi, et al.
Publicado: (2011)

Case of non‐secretory multiple myeloma eventually diagnosed by (18)F‐FDG PET/CT
por: Haratake, Daisuke, et al.
Publicado: (2022)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Cost-effectiveness analysis of MRI, CE-CT and 18F-FDG PET/CT for detecting colorectal liver metastases eligible for hepatic resection
por: Schnitzer, Moritz L., et al.
Publicado: (2023)

P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Illidge, T., et al.
Publicado: (2022)

FDG-PET in lymphoma
por: Meignan, Michel
Publicado: (2014)

PET-FDG: Impetus
por: Nanni, Cristina
Publicado: (2020)

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
por: Dumontet, Charles, et al.
Publicado: (2018)

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
por: Sonneveld, Pieter, et al.
Publicado: (2020)

Prognostic value of diffuse splenic FDG uptake on PET/CT in patients with gastric cancer
por: Yoon, Hai-Jeon, et al.
Publicado: (2018)

A case of lymphangioleiomyomatosis with diffuse large B-cell lymphoma: Usefulness of FDG-PET
por: Orimo, Mami, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7hgr26gmqmkbqib15l102gbnt6